Previous treatment with brentuximab vedotin will be allowed if it was done  months prior to enrollment and was not refractory to or had progressive disease (PD) on brentuximab vedotin (BV)
Pregnancy or breast-feeding women; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Brentuximab vedotin naive OR had at least stable disease by Lugano Classification to prior brentuximab vedotin treatment
History of prior >= grade  hypersensitivity to either brentuximab vedotin or nivolumab
Brentuximab vedotin
Prior treatment with at least  lines of therapy for HL including brentuximab vedotin; in those patients who cannot receive brentuximab vedotin, treatment with  prior therapeutic regimens is sufficient
Prior treatment with brentuximab vedotin is allowed provided the patient did not progress on BV or within  days of last dose of BV; patients must be at least  months from the last dose of BV
Previous exposure to brentuximab vedotin (BV)
Known hypersensitivity to brentuximab vedotin components
Histologically confirmed CD-positive (defined in this study as >= % expression) MF (including large cell transformation variant) or SS who have either:\r\n* Received prior systemic therapy (for whom commercial supply of brentuximab vedotin is available) OR\r\n* Not received prior systemic therapy (who will receive brentuximab vedotin free of charge)
Previous brentuximab treatment
Patient has hypersensitivity to brentuximab vedotin
Patients with prior receipt of brentuximab vedotin
Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within  months prior to registration, and must not have relapsed within  months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD/PDL axis agents; patients in the nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumab
Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
RANDOMIZED PHASE II (ARMS K AND L): Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within  months prior to registration, and must not have relapsed within  months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD/PDL axis agents; patients may not have received prior ipilimumab
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
Resolution of all non-hematologic brentuximab vedotin-related adverse events (AEs) to < grade 
Intolerance to brentuximab vedotin
Patients receiving chronic treatment with systemic steroids; however, patients can receive up to  days of steroid therapy prior to starting treatment with brentuximab vedotin (BV)+ doxorubicin, vinblastine, dacarbazine (AVD)
May have received either brentuximab vedotin or lenalidomide/immunomodulatory imide drugs (IMiD) without dose modification/delay due to toxicity\r\n* IMiDs defined as thalidomide analogues
If received prior brentuximab vedotin or lenalidomide, must be able to tolerate the dose level to which the participant will be enrolled to
Allergic reaction/hypersensitivity to lenalidomide or history of anaphylactic shock to brentuximab vedotin in the past
Previously untreated with either chemotherapy, radiation therapy or either brentuximab vedotin or nivolumab, or another check point inhibitor
Allergy to brentuximab vedotin and/or nivolumab
Prior treatment with brentuximab vedotin (BV)
Known allergy to bevacizumab or brentuximab vedotin or any of its excipients
Previously treated with brentuximab vedotin, immune-oncology agents, or received an allogeneic or autologous stem cell transplant
Subjects may be Brentuximab vedotin- nave, or may have had prior Brentuximab vedotin treatment (cohort A, B & C - enrolment closed)
Prior treatment with brentuximab vedotin is allowed provided the patient did not progress on BV or within  days of last dose of BV; patients must be at least  months from the last dose of BV
Previous primary progression or grade  toxicity on treatment with brentuximab vedotin
Participant may have failed to achieve a response or progressed after treatment with brentuximab vedotin or may be brentuximab vedotin nave
If female of childbearing age, negative serum pregnancy test within  days prior to the first dose of brentuximab vedotin in this study
Prior treatment with brentuximab vedotin and bendamustine in combination; may have received prior therapy with brentuximab vedotin or bendamustine separately
Received either brentuximab vedotin or bendamustine within  months of receiving their first dose of protocol based therapy
If brentuximab vedotin or bendamustine was previously received, had disease progression during the first  cycles of either brentuximab vedotin or bendamustine
Known hypersensitivity to brentuximab vedotin, bendamustine, or mannitol
Prior to day  of brentuximab vedotin, please verify the patient does not meet the criteria below:\r\n* Symptomatic pulmonary disease currently requiring regular medication including but not restricted to bronchodilators
Previous receipt of brentuximab vedotin Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Patients must have received at least  prior regimens and have received or be deemed ineligible for autologous stem cell transplant, and must have received prior brentuximab vedotin
Previous treatment with brentuximab vedotin
Prior use of brentuximab vedotin
Must have had prior treatment with brentuximab vedotin or not a candidate for treatment with brentuximab vedotin
Prior administration of brentuximab vedotin
Previous treatment with brentuximab vedotin or bendamustine.
No prior brentuximab vedotin
Patient has hypersensitivity to brentuximab vedotin
Patient has received other investigational drugs within  days before treatment of treatment with brentuximab vedotin
Viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
Previous treatment with brentuximab vedotin.
Prior use of brentuximab vedotin for GVHD is not allowed; prior use of brentuximab vedotin for the treatment of malignancy is allowed
Patient must not have had prior exposure to brentuximab vedotin
Prior use of brentuximab vedotin for GVHD is not allowed; prior use of brentuximab vedotin for the treatment of malignancy, i.e. Hodgkin lymphoma, anaplastic large cell lymphoma, etc. is allowed